{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T14:39:37Z","timestamp":1761489577583},"reference-count":36,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1053\/j.seminoncol.2015.02.001","type":"journal-article","created":{"date-parts":[[2015,2,24]],"date-time":"2015-02-24T03:15:39Z","timestamp":1424747739000},"page":"418-422","source":"Crossref","is-referenced-by-count":6,"title":["Immune Checkpoint Blockade in Malignant Mesothelioma"],"prefix":"10.1053","volume":"42","author":[{"given":"Luana","family":"Calabr\u00f2","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Maio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminoncol.2015.02.001_bib1","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1056\/NEJMra050152","article-title":"Advances in malignant mesothelioma","volume":"353","author":"Robinson","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2015.02.001_bib2","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1634\/theoncologist.12-7-850","article-title":"Multisciplinary treatment of malignant pleural mesothelioma","volume":"12","author":"Ceresoli","year":"2007","journal-title":"Oncologist"},{"key":"10.1053\/j.seminoncol.2015.02.001_bib3","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural meothelioma","volume":"21","author":"Volgelzang","year":"2003","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1053\/j.seminoncol.2015.02.001_bib4","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.lungcan.2011.08.011","article-title":"Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey","volume":"75","author":"Zucali","year":"2012","journal-title":"Lung Cancer"},{"key":"10.1053\/j.seminoncol.2015.02.001_bib5","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1200\/JCO.2006.09.9887","article-title":"A randomized phase III trial comparing pemetrexed plus best supportive care (BSC) versus BSC in previously treated patients with advanced malignant pleural mesothelioma","volume":"26","author":"Jassem","year":"2008","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1053\/j.seminoncol.2015.02.001_bib6","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.jtcvs.2007.10.026","article-title":"Impact of tumor-infiltrating T cells on survival in patients with malignant mesothelioma","volume":"135","author":"Anraku","year":"2008","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1053\/j.seminoncol.2015.02.001_bib7","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0169-5002(98)00014-2","article-title":"Sera from patients with malignant mesothelioma can contain autoantibodies","volume":"20","author":"Robinson","year":"1998","journal-title":"Lung Cancer"},{"key":"10.1053\/j.seminoncol.2015.02.001_bib8","doi-asserted-by":"crossref","first-page":"3814","DOI":"10.1158\/1078-0432.CCR-04-2304","article-title":"Humoral immune response to mesothelina in mesothelioma and ovarian cancer patients","volume":"11","author":"Ho","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminoncol.2015.02.001_bib9","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0169-5002(00)00192-6","article-title":"Palliative and therapeutic activity of IL-2 immunotherapy in unresectable malignant pleural mesothelioma with pleural effusion: results of a phase II on 31 consecutive patients","volume":"31","author":"Castagneto","year":"2001","journal-title":"Lung Cancer"},{"key":"10.1053\/j.seminoncol.2015.02.001_bib10","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ejca.2007.08.028","article-title":"Mesothelin targeted cancer immunotherapy","volume":"44","author":"Hassan","year":"2008","journal-title":"Eur J Cancer"},{"key":"10.1053\/j.seminoncol.2015.02.001_bib11","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.lungcan.2006.01.007","article-title":"Recombinant GM-CSF plus autologous tumor cells as a vaccine for patients with mesothelioma","volume":"52","author":"Powell","year":"2006","journal-title":"Lung Cancer"},{"key":"10.1053\/j.seminoncol.2015.02.001_bib12","doi-asserted-by":"crossref","first-page":"153","DOI":"10.4161\/cam.4.1.11361","article-title":"What\u2019s the place of immunotherapy in malignant mesothelioma treatments?","volume":"4","author":"Gr\u00e9goire","year":"2010","journal-title":"Cell Adh Migr"},{"key":"10.1053\/j.seminoncol.2015.02.001_bib13","doi-asserted-by":"crossref","first-page":"927240","DOI":"10.1155\/2012\/927240","article-title":"New roads open up for implementing immunotherapy in mesothelioma","volume":"2012","author":"Cornelissen","year":"2012","journal-title":"Clin Dev Immunol"},{"key":"10.1053\/j.seminoncol.2015.02.001_bib14","doi-asserted-by":"crossref","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","article-title":"Guidelines for the evaluation of immunotherapy activity in solid tumors: immune-related response criteria","volume":"15","author":"Wolchok","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1053\/j.seminoncol.2015.02.001_bib15","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s00262-014-1609-9","article-title":"CTLA4 blockade in mesothelioma: finally a competing strategy over cytotoxic\/target therapy?","volume":"64","author":"Calabr\u00f2","year":"2015","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"10.1053\/j.seminoncol.2015.02.001_bib16","doi-asserted-by":"crossref","first-page":"e27560","DOI":"10.4161\/onci.27560","article-title":"Harnessing the immune system to provide long-term survival in patients with melanoma and other solid tumors","volume":"3","author":"Eggermont","year":"2014","journal-title":"Oncoimmunology"},{"key":"10.1053\/j.seminoncol.2015.02.001_bib17","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1016\/j.ejca.2013.06.019","article-title":"Immunotherapy and the concept of a clinical cure","volume":"49","author":"Eggermont","year":"2013","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1053\/j.seminoncol.2015.02.001_bib18","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1053\/j.seminoncol.2010.09.006","article-title":"Clinical studies with anti-CTLA-4 antibodies in non-melanoma indications","volume":"37","author":"Calabr\u00f2","year":"2010","journal-title":"Semin Oncol"},{"issue":"17","key":"10.1053\/j.seminoncol.2015.02.001_bib19","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1200\/JCO.2011.38.4032","article-title":"Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB\/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study","volume":"30","author":"Lynch","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2015.02.001_bib20","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1053\/j.seminoncol.2010.09.007","article-title":"The emerging toxicity profiles of anti-CTLA4 antibodies across clinical indications","volume":"37","author":"Di Giacomo","year":"2010","journal-title":"Semin Oncol"},{"key":"10.1053\/j.seminoncol.2015.02.001_bib21","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1093\/annonc\/mdt161","article-title":"Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials","volume":"24","author":"Wolchok","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2015.02.001_bib22","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nrd4066","article-title":"New checkpoint inhibitors ride the immunotherapy tsunami","volume":"12","author":"Mullard","year":"2013","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"10.1053\/j.seminoncol.2015.02.001_bib23","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2217\/imt.13.9","article-title":"Tremelimumab: a review of development to date in solid tumors","volume":"5","author":"Tarhini","year":"2013","journal-title":"Immunotherapy"},{"key":"10.1053\/j.seminoncol.2015.02.001_bib24","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1200\/JCO.2012.44.6112","article-title":"Phase III randomized, clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma","volume":"31","author":"Ribas","year":"2013","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1053\/j.seminoncol.2015.02.001_bib25","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/S1470-2045(13)70381-4","article-title":"Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial","volume":"14","author":"Calabr\u00f2","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.seminoncol.2015.02.001_bib26","first-page":"e27482","article-title":"Immune checkpoint blockade in malignant mesothelioma","volume":"3","author":"Calabr\u00f2","year":"2014","journal-title":"A novel therapeutic strategy against a deadly disease? OncoImmunology"},{"key":"10.1053\/j.seminoncol.2015.02.001_bib27","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1007\/s00262-013-1418-6","article-title":"Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg\/kg within an expanded access programme","volume":"62","author":"Di Giacomo","year":"2013","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"10.1053\/j.seminoncol.2015.02.001_bib28","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/S1470-2045(13)70573-4","article-title":"Biomarkers for immune checkpoint inhibitors","volume":"15","author":"Calabr\u00f2","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.seminoncol.2015.02.001_bib29","article-title":"A phase 2 single-arm study with tremelimumab at an optimized dosing schedule in second-line mesothelioma patients","volume":"32","author":"Calabro\u2019","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2015.02.001_bib30","article-title":"Pharmacokinetics of tremelimumab, a fully human anti-CTLA-4 monoclonal antibody, in subjects with unresectable malignant mesothelioma","author":"Calabr\u00f2","year":"2014","journal-title":"Paper presented at the Annual Meeting of the American Association for Cancer Research"},{"key":"10.1053\/j.seminoncol.2015.02.001_bib31","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/annonc\/mdh059","article-title":"Modified RECIST criteria for assessment of response in malignant pleural mesothelioma","volume":"15","author":"Byrne","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2015.02.001_bib32","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1053\/j.seminoncol.2015.02.001_bib33","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1053\/j.seminoncol.2015.02.001_bib34","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1158\/1078-0432.CCR-13-3271","article-title":"Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy","volume":"20","author":"Taube","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1053\/j.seminoncol.2015.02.001_bib35","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1302369","article-title":"Nivolumab plus ipilimumab in advanced melanoma","volume":"369","author":"Wolchock","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2015.02.001_bib36","doi-asserted-by":"crossref","first-page":"5s","DOI":"10.1200\/jco.2014.32.15_suppl.7589","article-title":"T-cell inflamed phenotype and PD-L1 expression in malignant mesothelioma","volume":"32","author":"Kindler","year":"2014","journal-title":"J Clin Oncol"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775415000172?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775415000172?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,21]],"date-time":"2019-08-21T05:25:48Z","timestamp":1566365148000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775415000172"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["S0093775415000172"],"URL":"https:\/\/doi.org\/10.1053\/j.seminoncol.2015.02.001","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2015,6]]}}}